Clinical Study

Antioxidant Effects of a Hydroxytyrosol-Based Pharmaceutical Formulation on Body Composition, Metabolic State, and Gene Expression: A Randomized Double-Blinded, Placebo-Controlled Crossover Trial

Table 3

Plasmatic and erythrocyte membrane PUFA concentrations after HTT and PT.

PUFAsParameterBaseline (T0)HTTpBaseline (T2)PTp
Mean ± SD
()
Mean ± SD
()
Mean ± SD
()
Mean ± SD
()

PlasmaticAA/EPA24.33 ± 29.5121.47 ± 20.150.4019.18 ± 29.1517.39 ± 14.440.71
PlasmaticAA/DHA2.28 ± 0.772.43 ± 0.700.062.29 ± 0.622.46 ± 0.830.22
Erythrocytes membraneAA/EPA60.60 ± 87.2054.24 ± 76.750.1251.60 ± 74.6550.26 ± 63.030.77
Erythrocytes membraneAA/DHA3.51 ± 0.873.39 ± 0.780.073.40 ± 0.813.46 ± 0.990.56

All parameters were evaluated before and after HTT. All results were expressed as mean ± standard deviation (SD) (number of replicates = 3). PT: placebo treatment; HTT: 15 mg/day hydroxytyrosol treatment; AA: arachidonic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid.